Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Symbol: 002693.SZ

SHZ

5.69

CNY

Market price today

  • -39.5632

    P/E Ratio

  • 2.2749

    PEG Ratio

  • 2.36B

    MRK Cap

  • 0.00%

    DIV Yield

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ). Companys revenue shows the average of 212.148 M which is 0.079 % gowth. The average gross profit for the whole period is 144.08 M which is 0.085 %. The average gross profit ratio is 0.676 %. The net income growth for the company last year performance is 4.972 % which equals -2.305 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hainan Shuangcheng Pharmaceuticals Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.118. In the realm of current assets, 002693.SZ clocks in at 135.236 in the reporting currency. A significant portion of these assets, precisely 31.904, is held in cash and short-term investments. This segment shows a change of -0.781% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 10, if any, in the reporting currency. This indicates a difference of 13.709% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 135 in the reporting currency. This figure signifies a year_over_year change of -0.293%. Shareholder value, as depicted by the total shareholder equity, is valued at 471.486 in the reporting currency. The year over year change in this aspect is -0.082%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 16.359, with an inventory valuation of 74.31, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 171.78. Account payables and short-term debt are 17.14 and 10.05, respectively. The total debt is 145.05, with a net debt of 141.66. Other current liabilities amount to 2.04, adding to the total liabilities of 285.6. Lastly, the referred stock is valued at 34.43, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

291.4131.914677
100
95.5
68.1
31.7
25
246.2
85.4
346.8
446.8
33.6
149.8
9.9

balance-sheet.row.short-term-investments

223.2728.5133.855.4
94.3
52.8
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

97.0116.44133.1
44.6
82.2
69.2
244.7
84.2
201.1
102.7
65.8
36.1
50.4
23.9
16.4

balance-sheet.row.inventory

306.6174.365.455.2
52.8
47.6
86.3
119.9
34.2
28.3
53.1
30.6
23.5
12.2
10.4
9.8

balance-sheet.row.other-current-assets

0.250.200.1
0
0
148.6
161.7
8
3.4
380
220
161
-0.8
-2.5
-4.3

balance-sheet.row.total-current-assets

721.6135.2252.4165.4
197.5
225.4
372.1
557.9
151.4
479
621.2
663.2
667.4
95.5
181.6
31.8

balance-sheet.row.property-plant-equipment-net

1823.92457.6471.8504.7
541
601.1
637.8
679.5
658.9
443.2
264.1
213.3
182.1
133.8
54.2
53.4

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

688.05171.8164.9156.9
134.4
115.2
96.5
101.2
105.9
134.2
48.2
33.5
33.3
18.2
16.4
12.1

balance-sheet.row.goodwill-and-intangible-assets

688.05171.8164.9156.9
134.4
115.2
96.5
101.2
105.9
134.2
48.2
33.5
33.3
18.2
16.4
12.1

balance-sheet.row.long-term-investments

44.81108.817.3
25.9
3.1
3.3
3.7
215.1
412.9
0
0
0
0
0
0

balance-sheet.row.tax-assets

4.761.511
0.7
0.7
1.5
1.2
3
5.9
4
2.6
2.4
0.3
0.2
0.2

balance-sheet.row.other-non-current-assets

83.1727.112.29.1
8.3
5.4
9
37.3
246.4
487.9
6
4.4
1.5
0.2
0.2
0.3

balance-sheet.row.total-non-current-assets

2644.71668658.6689.1
710.2
725.6
748.1
819.2
1014.1
1071.1
322.3
253.9
219.3
152.6
71.1
66

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

3366.32803.2911854.6
907.7
951
1120.2
1377.1
1165.5
1550.2
943.5
917
886.7
248.1
252.7
97.9

balance-sheet.row.account-payables

61.5817.115.517.2
15.4
9.9
11.8
80.5
28.5
13.2
8.9
10.7
10.7
7.1
3.9
7.5

balance-sheet.row.short-term-debt

388.310.1205.30.3
55.7
0.3
0
0
190
345
0
0
0
0
0
0

balance-sheet.row.tax-payables

13.43.712.87.2
6.3
10.1
5.3
8.8
4.5
11.9
7.2
8.3
6.7
4
4.5
4.5

balance-sheet.row.long-term-debt-total

290.021350167
167
167
306
367
297
145
0
0
0
0
0
0

Deferred Revenue Non Current

31.2687.68.9
10.3
10.5
31.1
32.8
33.8
32
26.6
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

11.26---
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

9.06273.61.8
1.5
13.3
95
120.1
36.6
86.5
13.8
18.3
14.3
10.7
89.3
10.6

balance-sheet.row.total-non-current-liabilities

332.55145.710.7179.4
180
179.1
343.7
414.8
357.3
177.9
27.3
17.4
15.9
2.1
1.8
1.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1177.06285.6330.1287.8
309.4
272.7
450.6
615.4
612.4
622.6
50
46.4
40.8
19.8
94.9
19.9

balance-sheet.row.preferred-stock

68.8534.400
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1666.33416.7414.7412
405
405
405
405
405
419.2
270
180
120
90
90
5

balance-sheet.row.retained-earnings

-1287.93-347-296.2-305.2
-284.6
-231.3
-256
-186.5
-192.8
195.6
174.1
157.1
138.9
77.7
14.3
65.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

501.27-0.487.282.2
86
86
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1044.52367.6307.9292.9
286.5
286.5
373
372.9
340.9
312.8
449.4
533.6
586.9
60.5
53.5
7.2

balance-sheet.row.total-stockholders-equity

1993.04471.5513.5481.8
492.9
546.3
522.1
591.4
553.1
927.6
893.6
870.6
845.8
228.2
157.8
77.9

balance-sheet.row.total-liabilities-and-stockholders-equity

3366.32803.2911854.6
907.7
951
1120.2
1377.1
1165.5
1550.2
943.5
917
886.7
248.1
252.7
97.9

balance-sheet.row.minority-interest

196.2246.267.484.9
105.4
132
147.6
170.3
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

2189.26517.6580.9566.8
598.3
678.3
669.7
761.7
553.1
927.6
893.6
870.6
845.8
228.2
157.8
77.9

balance-sheet.row.total-liabilities-and-total-equity

3366.32---
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

206.6310133.855.4
94.3
52.8
3.3
0
207
477.3
0
0
0
0
0
0

balance-sheet.row.total-debt

678.32145.1205.3167.3
222.7
167.3
306
367
487
490
0
0
0
0
0
0

balance-sheet.row.net-debt

610.18141.7193.1145.6
216.9
124.6
237.9
335.3
462
243.8
-85.4
-346.8
-446.8
-33.6
-149.8
-9.9

Cash Flow Statement

The financial landscape of Hainan Shuangcheng Pharmaceuticals Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -3.836. The company recently extended its share capital by issuing 0, marking a difference of 0.480 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 19.57 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -85071692.340 in the reporting currency. This is a shift of -3.578 from the previous year. In the same period, the company recorded 57.54, 0, and -12, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -11.13 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 68.07, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

-63.99-8.5-40.8-79.9
9
-92.1
1.3
-388.4
52.7
58.9
66.8
68
70.4
64.2
32.1

cash-flows.row.depreciation-and-amortization

40.3857.554.357.1
59
56.1
43.5
29.2
20.7
17.4
12.6
7.6
5.7
5
3.7

cash-flows.row.deferred-income-tax

-3.82-0.40.41.2
1.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

1.426.97.2-1.2
-1.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-10.62-4.514.9-12.2
26.1
60.4
-37.2
112
-29.2
-12.3
-10.9
5.7
-10.3
-12.1
5

cash-flows.row.account-receivables

4.99-13.85.439.8
8.2
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-12.45-9.9-4.8-4.3
39.6
31.3
-89.6
-6.2
14.2
-22.4
-7.2
-11.3
-1.8
-0.6
-2.4

cash-flows.row.account-payables

019.613.8-48.9
-23.2
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-3.17-0.40.41.2
1.5
29.1
52.3
118.2
-43.4
10.2
-3.7
16.9
-8.5
-11.5
7.4

cash-flows.row.other-non-cash-items

45.94-25.8-12.524.5
-27.6
22.5
-30.1
285.8
2.1
-13
-12
-1.1
0.3
-1.8
3.5

cash-flows.row.net-cash-provided-by-operating-activities

7.88000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-50.56-33-31.6-51.6
-51.5
-22.4
-70.2
-183
-289.7
-115.9
-65.1
-57.9
-107.1
-9.5
-23.3

cash-flows.row.acquisitions-net

14.272721.753.6
74
0
0.7
2
0.1
0
65.1
57.9
0
-1
0

cash-flows.row.purchases-of-investments

-193.85-471-256.2-637.2
-507.6
-775.3
-315.3
-8
-835.3
-1850
-2070.6
-441
0
-160
0

cash-flows.row.sales-maturities-of-investments

263.71391.9299.2615.3
599.4
915.9
302
6.4
729
1704
2024
280.9
0
161.4
0

cash-flows.row.other-investing-activites

13.0800-51.6
-51.5
7.6
12.7
2.2
-0.7
-15.1
-65.1
-57.9
0
0
0.1

cash-flows.row.net-cash-used-for-investing-activites

16.89-85.133-71.5
62.8
125.9
-69.9
-180.4
-396.5
-277.1
-111.7
-218
-107.1
-9.2
-23.2

cash-flows.row.debt-repayment

-92.11-12-55.3-1.8
-139
-106
-475
-196.4
-70
0
0
0
0
0
-16

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-7.78-11.1-9.1-9.8
-10.1
-16.7
-7.5
-25.2
-43
-36
-44
0
-75.1
0
-16.3

cash-flows.row.other-financing-activites

35.6468.123.857
-5.3
-11.4
586.6
209.8
553.9
0
0
550
0
93.7
16

cash-flows.row.net-cash-used-provided-by-financing-activities

-13.0244.9-40.645.4
-154.3
-134
104.1
-11.7
440.9
-36
-44
550
-75.1
93.7
-16.3

cash-flows.row.effect-of-forex-changes-on-cash

0.010.1-0.1-0.3
0
-2.7
-3.4
1.1
0.7
-0.3
0
0.1
-0.1
0
0

cash-flows.row.net-change-in-cash

11.76-14.815.8-36.9
-24.9
36
8.2
-152.4
91.4
-262.4
-99.2
412.4
-116.2
139.9
4.8

cash-flows.row.cash-at-end-of-period

68.146.821.65.8
42.7
67.6
31.6
23.4
175.8
84.4
346.8
446
33.6
149.8
9.9

cash-flows.row.cash-at-beginning-of-period

56.3821.65.842.7
67.6
31.6
23.4
175.8
84.4
346.8
446
33.6
149.8
9.9
5.2

cash-flows.row.operating-cash-flow

7.8825.223.6-10.5
66.6
46.8
-22.5
38.6
46.2
51
56.4
80.2
66.1
55.3
44.3

cash-flows.row.capital-expenditure

-50.56-33-31.6-51.6
-51.5
-22.4
-70.2
-183
-289.7
-115.9
-65.1
-57.9
-107.1
-9.5
-23.3

cash-flows.row.free-cash-flow

-42.68-7.8-8.1-62.1
15.1
24.5
-92.7
-144.3
-243.4
-64.9
-8.6
22.3
-41.1
45.8
20.9

Income Statement Row

Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s revenue saw a change of -0.141% compared with the previous period. The gross profit of 002693.SZ is reported to be 161.07. The company's operating expenses are 183.42, showing a change of -14.998% from the last year. The expenses for depreciation and amortization are 57.54, which is a -0.085% change from the last accounting period. Operating expenses are reported to be 183.42, which shows a -14.998% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -1.988% year-over-year growth. The operating income is -73.15, which shows a 1.988% change when compared to the previous year. The change in the net income is 4.972%. The net income for the last year was -50.74.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

197.21235.9274.8320.3
269.4
346.6
337.2
246.8
145.1
231
161.2
149.6
129.7
133.5
112.9
88.2

income-statement-row.row.cost-of-revenue

68.1474.988.381.4
60.2
95.1
120.9
91.5
69.9
102.1
55.9
52.8
37.1
33.7
28.4
28.9

income-statement-row.row.gross-profit

129.06161.1186.5238.9
209.3
251.5
216.4
155.3
75.2
128.8
105.3
96.8
92.5
99.8
84.5
59.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

8.41---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

20.73---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

80.37---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0.190.263.269
69.7
41.5
-3.1
2.2
4.2
5.1
-0.4
3.5
6.6
2.5
0.6
0.9

income-statement-row.row.operating-expenses

164.04183.4215.8282.7
264.6
272.7
283.8
182.9
179.3
73.4
54.2
42
26.5
23.6
15.1
20.8

income-statement-row.row.cost-and-expenses

232.18258.3304.1364.1
324.8
367.8
404.7
274.4
249.2
175.5
110.1
94.7
63.7
57.3
43.4
49.7

income-statement-row.row.interest-income

0.0400.10.1
0.1
0.6
0.3
0.3
0.2
0.9
5
7.9
6.2
1.6
0.3
0

income-statement-row.row.interest-expense

9.049.611.29
10
9.8
17.5
16.6
15.3
16.1
4.6
0
0
0
0
0.3

income-statement-row.row.selling-and-marketing-expenses

80.37---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-58.06-50.615.62
-25.6
24.3
-25.9
30.7
-281
6.8
18
23.8
13.9
3.8
2.7
-2.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.190.263.269
69.7
41.5
-3.1
2.2
4.2
5.1
-0.4
3.5
6.6
2.5
0.6
0.9

income-statement-row.row.total-operating-expenses

-58.06-50.615.62
-25.6
24.3
-25.9
30.7
-281
6.8
18
23.8
13.9
3.8
2.7
-2.6

income-statement-row.row.interest-expense

9.049.611.29
10
9.8
17.5
16.6
15.3
16.1
4.6
0
0
0
0
0.3

income-statement-row.row.depreciation-and-amortization

32.9852.757.554.3
57.1
59
56.1
43.5
29.2
20.7
17.4
12.6
7.6
5.7
5
3.7

income-statement-row.row.ebitda-caps

-31.85---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-87.45-73.2-24.5-42.3
-53.2
-13.7
-90.2
0.9
-389.1
57.4
69.7
75.2
73.3
77.9
71.5
38.7

income-statement-row.row.income-before-tax

-87.26-73-8.9-40.4
-78.8
10.5
-93.4
3.1
-385.1
62.3
69.1
78.6
80
80
72.2
35.9

income-statement-row.row.income-tax-expense

-12.63-1-0.40.4
1.2
1.5
-1.2
1.8
3.3
9.6
10.2
11.9
12
9.6
7.9
3.8

income-statement-row.row.net-income

-63.99-50.7-8.5-40.8
-79.9
9
-69.5
6.3
-388.4
52.7
58.9
66.8
68
70.4
64.2
32.1

Frequently Asked Question

What is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) total assets?

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) total assets is 803248121.000.

What is enterprise annual revenue?

The annual revenue is 96442813.000.

What is firm profit margin?

Firm profit margin is 0.654.

What is company free cash flow?

The free cash flow is -0.103.

What is enterprise net profit margin?

The net profit margin is -0.324.

What is firm total revenue?

The total revenue is -0.443.

What is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) net profit (net income)?

The net profit (net income) is -50741578.370.

What is firm total debt?

The total debt is 145050750.000.

What is operating expences number?

The operating expences are 183423820.000.

What is company cash figure?

Enretprise cash is 17684279.000.